Form D · Biotechnology

Circle Biologics, Inc.

Minneapolis, MN · CIK 0001543622

Offering snapshot reported Oct 25, 2012 · SEC filing

Reported sold
$617K
Offering amount: $1.5M
Investors reported
5
Form D · investor count
Minimum accepted
$100K
Reported outside-investor minimum
First sale
Jul 20, 2012
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$308K$617KAug 20, 2012: $300,000.00Aug 20, 2012Sep 19, 2012: $466,666.00Sep 19, 2012Oct 25, 2012: $616,666.00Oct 25, 2012

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$466,666 → $616,666
  • Reported investors4 → 5

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 25, 2012Amendment$616,666$150,000vs Sep 19, 20125SEC filing
Sep 19, 2012Amendment$466,666$166,666vs Aug 20, 20124SEC filing
Aug 20, 2012Initial$300,000No comparison3SEC filing
Aug 9, 2012Initial$100,000No comparison1SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-182937

Source: Form D, filed Oct 25, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Elizabeth Coull Director
Fred Kolb Director
Matthew Kyle Executive
Richard F. Kyle, M.D. Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3650 Annapolis Lane Suite 105
Minneapolis, MN, 55447